Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Sep 24, 2024; 15(9): 1207-1214
Published online Sep 24, 2024. doi: 10.5306/wjco.v15.i9.1207
Blastic plasmacytoid dendritic cell neoplasm: Two case reports
Yi-Qian Ma, Zhan Sun, Yu-Mei Li, Hui Xu
Yi-Qian Ma, Zhan Sun, Yu-Mei Li, Hui Xu, Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang 212000, Jiangsu Province, China
Author contributions: Xu H, Li YM designed the research and supervised the paper; Xu H, Li YM, Ma YQ and Sun Z performed the research; Ma YQ and Sun Z analyzed the data; Xu H, Ma YQ and Sun Z wrote the paper; Xu H provided case information; All the authors contributed to the revision.
Supported by The National Key Research and Development Programs of China, No. 2022YFC2603801; Maternal and Child Health Project of Jiangsu Province, No. F201717; Doctor Project of Affiliated Hospital of Jiangsu University, No. jdfyrc2019003; and Clinical and Virology Study of 2019-ncov Infection in Patients with Moderate to Severe Psoriasis, No. Jdfyxgzx005.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hui Xu, PhD, Professor, Department of Dermatology, The Affiliated Hospital of Jiangsu University, No. 438 Jiefang Road, Zhenjiang 212000, Jiangsu Province, China. xuhuiraian@sina.com
Received: October 24, 2023
Revised: February 7, 2024
Accepted: June 3, 2024
Published online: September 24, 2024
Processing time: 309 Days and 20.1 Hours
Core Tip

Core Tip: This article reported on 2 cases of blastic plasmacytoid dendritic cell tumor (BPDCN) patients diagnosed and treated in our hospital, describing clinical manifestations, laboratory examination, and treatment process. A summarization of the current literature, combined with the experience of these 2 patients, allowed for our reasoned overall conclusions. Based on the 2-patient experience, BPDCN as a hematologic malignancy has a very poor prognosis. Treatment with acute lymphoblastic leukemia chemotherapy is effective in some way. Venetoclax, a BCL-2 inhibitor, can partially subside skin lesions. Unless stem cell transplantation is used, there is no significant improvement in overall survival time.